HOME >> MEDICINE >> NEWS
The Lancet Oncology (TLO) and the Lancet Infectious Diseases (TLID)

This month's Leading Edge editorial discusses the difference between perception of risk and the actual risk by drawing upon two recent examples: breast cancer and the pill, and cannabis smoking and cancer risk. In both situations, scientific evidence does not appear to be affecting the public's misperception of absolute risk, and more worryingly, in the case of cannabis smoking, even nationwide policy is being lead by personal views rather than scientific evidence.

The editorial concludes: "Unravelling a misguided perception of risk from the real facts is a difficult task, but it is essential if the perpetuation of poorly conceived ideas is to stop. In light of the current trend towards chemoprevention to reduce a person's risk of contracting cancer, it is important that the general public do not become disenfranchised from the medical community by exposure to over-reporting of contradictory reports in the popular media. Only then will cancer risk truly decrease by informed changes in lifestyle."

Reviews:

Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention

Cigarette smoking and the risk of endometrial cancer

Strategic marketing in the UK tobacco industry

Hyperthermia in combined treatment of cancer

Metastasis to and from the central nervous system-the "relatively protected site"

Stem-cell origin of metastasis and heterogeneity of solid tumours

The Lancet Infectious Diseases (TLID)

Combination antiretroviral therapies are widely used for the treatment of HIV but it is unclear whether they will continue to be effective in the face of quickly evolved drug-resistant strains of HIV, and increased risky sexual behaviour in certain communities. In the August issue of The Lancet Infectious Diseases, J X Velasco-Hernandez and colleagues, from the Instituto Mexicano del Petroleo, San Bartolo, Mexico, and the UCLA School of Medicine, Los Angeles, US
'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-20-7424-4949
Lancet
31-Jul-2002


Page: 1 2

Related medicine news :

1. The Lancet calls for the creation of a world institute for risk evaluation
2. The Lancet calls for creation of Intl Commission on Global Responses to Complex Emergencies
3. Majority of authors retract 1998 Lancet paper-Lancet editor points to implications
4. The Lancet Oncology (TLO)
5. The Lancet Infectious Diseases (TLID)
6. The Lancet Neurology November press release
7. Lancet readers to join WHO election debate
8. The Lancet Oncology press release
9. The Lancet Neurology October press release
10. The Lancet neurology press release
11. The Lancet Neurology press release

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: The Lancet Oncology TLO and the Lancet Infectious Diseases TLID

(Date:7/24/2014)... (PRWEB) July 24, 2014 The ... Association (AOA) and the Entertainment Industries Council (EIC) ... TV series American Horror Story on a first-of-its-kind ... the dramatic realities of illegal and unsafe lens ... which has already reached tens-of-thousands, is now releasing ...
(Date:7/24/2014)... -- A new formulation of a powerful narcotic painkiller ... drug has been approved by the U.S. Food and ... Purdue Pharma, the pill is a combination of the ... euphoric effects of oxycodone. The naloxone is only activated ... according to the FDA. While Targiniq has only ...
(Date:7/24/2014)... 17, 2014, Cleveland: Could the body,s own immune system ... associated with conditions like chronic epilepsy, Alzheimer,s dementia and ... study published online by PLOS ONE . , ... known as S100B, which serves as a biomarker for ... brain and spinal column. However, following a brain injury, ...
(Date:7/24/2014)... July 24, 2014 National Analysts Worldwide, ... that it will operate globally under the name, ... a woman-owned Employee Stock Ownership Plan (ESOP) organization led ... McDonald, Ph.D . The firm guides market strategy ... analytics. , Said McDonald, “We wanted our name ...
(Date:7/24/2014)... The report, “Feed Palatability Enhancers & Modifiers ... Poultry, Cattle, Pets, Aquaculture, and Others) - Global Trends ... palatability enhancers & modifiers market with an analysis and ... of types of feed flavors, sweeteners, and text rants. ... spread through 275 pages and in-depth TOC on "Feed ...
Breaking Medicine News(10 mins):Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 2Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 3Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 4Health News:FDA Approves Hard-to-Abuse Narcotic Painkiller 2Health News:Immune response may cause harm in brain injuries, disorders 2Health News:National Analysts Worldwide Announces a Change of Name to NAXION 2Health News:National Analysts Worldwide Announces a Change of Name to NAXION 3Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 2Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 3Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 4
(Date:7/24/2014)...  Blueprint Medicines (Blueprint), a leader in discovering highly ... announced the appointment of Jeffrey Albers as ... Algeta ASA, where he served on the executive management ... Bayer. Mr. Albers succeeds Alexis Borisy , co-founder ... Rock Ventures, who will remain an active member of ...
(Date:7/24/2014)... SAN DIEGO , July 24, 2014 /PRNewswire/ ... the industry leader in bioactive lipid-targeted therapeutics, reported ... trial where ASONEP™ is being investigated as a ... patients that have failed at least one therapy ... and no more than one mTOR inhibitor (e.g., ...
(Date:7/24/2014)... 24, 2014  Market Diagnostics International LLC ("MDxI") ... LabFile , a data resource that sets a ... universe and identifying target In Vitro Diagnostics (IVD) ... that provides IVD manufacturers with accurate and comprehensive ... clear and consistent definitions of laboratory categories and ...
Breaking Medicine Technology:Blueprint Medicines Appoints Jeffrey Albers as Chief Executive Officer 2Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 2Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 3Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 4MDxI Launches Data Resource Setting New Standard for Defining and Targeting US Clinical Laboratory Universe 2
Cached News: